{"id":"https://openalex.org/W1988024463","doi":"https://doi.org/10.2133/dmpk.18.365","title":"The Intestinal First-pass Metabolism of Substrates of CYP3A4 and P-glycoprotei\u2014Quantitative Analysis Based on Information from the Literature","display_name":"The Intestinal First-pass Metabolism of Substrates of CYP3A4 and P-glycoprotei\u2014Quantitative Analysis Based on Information from the Literature","publication_year":2003,"publication_date":"2003-01-01","ids":{"openalex":"https://openalex.org/W1988024463","doi":"https://doi.org/10.2133/dmpk.18.365","mag":"1988024463","pmid":"https://pubmed.ncbi.nlm.nih.gov/15618757"},"language":"en","primary_location":{"id":"doi:10.2133/dmpk.18.365","doi":"https://doi.org/10.2133/dmpk.18.365","is_oa":false,"landing_page_url":"https://doi.org/10.2133/dmpk.18.365","pdf_url":null,"source":{"id":"https://openalex.org/S185835163","display_name":"Drug Metabolism and Pharmacokinetics","issn_l":"1347-4367","issn":["1347-4367","1880-0920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Pharmacokinetics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078387402","display_name":"Motohiro Kato","orcid":"https://orcid.org/0000-0001-5145-1774","observed_orcids":["https://orcid.org/0000-0001-5145-1774"]},"institutions":[{"id":"https://openalex.org/I4405254473","display_name":"Chugai Pharmaceutical Co., Ltd. (Japan)","ror":"https://ror.org/01v743b94","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405254473"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Motohiro Kato","raw_affiliation_strings":["Pre-clinical Research Dept. I, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan. katomth@chugai-pharm.co.jp","Pre-clinical Research Dept. I, Chugai Pharmaceutical Co. Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pre-clinical Research Dept. I, Chugai Pharmaceutical Co. Ltd., Shizuoka, Japan. katomth@chugai-pharm.co.jp","institution_ids":["https://openalex.org/I4405254473"]},{"raw_affiliation_string":"Pre-clinical Research Dept. I, Chugai Pharmaceutical Co. Ltd","institution_ids":["https://openalex.org/I4405254473"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073045024","display_name":"K\u014dji Chiba","orcid":"https://orcid.org/0000-0001-7600-7813","observed_orcids":["https://orcid.org/0000-0001-7600-7813"]},"institutions":[{"id":"https://openalex.org/I4210148786","display_name":"Pfizer (Japan)","ror":"https://ror.org/05pm71w80","country_code":"JP","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4210148786"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Koji Chiba","raw_affiliation_strings":["Clinical Pharmacology Group, Pfizer Japan Inc., Tokyo, Japan","Clinical Pharmacology Group, Pfizer Japan Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Group, Pfizer Japan Inc., Tokyo, Japan","institution_ids":["https://openalex.org/I4210148786"]},{"raw_affiliation_string":"Clinical Pharmacology Group, Pfizer Japan Inc","institution_ids":["https://openalex.org/I4210148786"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053805209","display_name":"Akihiro Hisaka","orcid":"https://orcid.org/0000-0003-4863-9308","observed_orcids":["https://orcid.org/0000-0003-4863-9308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akihiro Hisaka","raw_affiliation_strings":["Clinical Pharmacology & Development, Banyu Pharmaceutical Co. Ltd., Tokyo, Japan","Clinical Pharmacology & Development, Banyu Pharmaceutical Co. Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Development, Banyu Pharmaceutical Co. Ltd., Tokyo, Japan","institution_ids":[]},{"raw_affiliation_string":"Clinical Pharmacology & Development, Banyu Pharmaceutical Co. Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054633553","display_name":"Michi Ishigami","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michi Ishigami","raw_affiliation_strings":["Clinical Pharmacology Department, Sankyo Co. Ltd., Tokyo, Japan","Clinical Pharmacology Department, Sankyo Co. Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Department, Sankyo Co. Ltd., Tokyo, Japan","institution_ids":[]},{"raw_affiliation_string":"Clinical Pharmacology Department, Sankyo Co. Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041826252","display_name":"Makoto Kayama","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Makoto Kayama","raw_affiliation_strings":["Project Coordination Department, Yamanouchi Pharmacentical Co. Ltd., Tokyo, Japan","Project Coordination Department, Yamanouchi Pharmacentical Co. Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Project Coordination Department, Yamanouchi Pharmacentical Co. Ltd., Tokyo, Japan","institution_ids":[]},{"raw_affiliation_string":"Project Coordination Department, Yamanouchi Pharmacentical Co. Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075850792","display_name":"Naomi Mizuno","orcid":"https://orcid.org/0000-0002-1326-9792","observed_orcids":["https://orcid.org/0000-0002-1326-9792"]},"institutions":[{"id":"https://openalex.org/I1306287861","display_name":"Mitsubishi Group (Japan)","ror":"https://ror.org/0234cd281","country_code":"JP","type":"company","lineage":["https://openalex.org/I1306287861"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Naomi Mizuno","raw_affiliation_strings":["Pharmacokinetics Laboratory, Mitsubishi Pharma, Co., Ltd., Kisarazu, Japan","Pharmacokinetics Laboratory, Mitsubishi Pharma, Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetics Laboratory, Mitsubishi Pharma, Co., Ltd., Kisarazu, Japan","institution_ids":["https://openalex.org/I1306287861"]},{"raw_affiliation_string":"Pharmacokinetics Laboratory, Mitsubishi Pharma, Co., Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053218019","display_name":"Yoshinori Nagata","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yoshinori Nagata","raw_affiliation_strings":["Pharmacokinetic Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan","Pharmacokinetic Research Laboratories, Kyowa Hakko Kogyo Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacokinetic Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan","institution_ids":[]},{"raw_affiliation_string":"Pharmacokinetic Research Laboratories, Kyowa Hakko Kogyo Co., Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Susumu Takakuwa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55881946","display_name":"Eisai (Japan)","ror":"https://ror.org/04vvh7p27","country_code":"JP","type":"company","lineage":["https://openalex.org/I55881946"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Susumu Takakuwa","raw_affiliation_strings":["Drug Metabolism and Pharmacokinetics Section, Eisai Co., Ltd, Tsukuba, Japan","Drug Metabolism and Pharmacokinetics Section, Eisai Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics Section, Eisai Co., Ltd, Tsukuba, Japan","institution_ids":["https://openalex.org/I55881946"]},{"raw_affiliation_string":"Drug Metabolism and Pharmacokinetics Section, Eisai Co., Ltd","institution_ids":["https://openalex.org/I55881946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110460516","display_name":"Yuko Tsukamoto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I4210105804","display_name":"Novartis (Japan)","ror":"https://ror.org/01k1ftz35","country_code":"JP","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210105804"]}],"countries":["CH","JP"],"is_corresponding":false,"raw_author_name":"Yuko Tsukamoto","raw_affiliation_strings":["Clinical Pharmacology Department., Novartis Pharma K.K., Tokyo, Japan","Clinical Pharmacology Department., Novartis Pharma K.K"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Department., Novartis Pharma K.K., Tokyo, Japan","institution_ids":["https://openalex.org/I4210105804"]},{"raw_affiliation_string":"Clinical Pharmacology Department., Novartis Pharma K.K","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105367376","display_name":"Kaoru Ueda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kaoru Ueda","raw_affiliation_strings":["Planning & Control Department. Teikoku Hormone MFG. Co., Ltd., Kanagawa, Japan","Planning & Control Department. Teikoku Hormone MFG. Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Planning & Control Department. Teikoku Hormone MFG. Co., Ltd., Kanagawa, Japan","institution_ids":[]},{"raw_affiliation_string":"Planning & Control Department. Teikoku Hormone MFG. Co., Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061014418","display_name":"Hiroyuki Kusuhara","orcid":"https://orcid.org/0000-0002-3641-8746","observed_orcids":["https://orcid.org/0000-0002-3641-8746"]},"institutions":[{"id":"https://openalex.org/I74801974","display_name":"The University of Tokyo","ror":"https://ror.org/057zh3y96","country_code":"JP","type":"education","lineage":["https://openalex.org/I74801974"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroyuki Kusuhara","raw_affiliation_strings":["Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan","Graduate School of Pharmaceutical Sciences, The University of Tokyo;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan","institution_ids":["https://openalex.org/I74801974"]},{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, The University of Tokyo;","institution_ids":["https://openalex.org/I74801974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101157872","display_name":"Kiyomi Ito","orcid":"https://orcid.org/0000-0002-0920-251X","observed_orcids":["https://orcid.org/0000-0002-0920-251X"]},"institutions":[{"id":"https://openalex.org/I36296616","display_name":"Hoshi University","ror":"https://ror.org/01mrvbd33","country_code":"JP","type":"education","lineage":["https://openalex.org/I36296616"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Kiyomi Ito","raw_affiliation_strings":["Department of Clinical Pharmacokinetics, Hoshi University, Tokyo, Japan","Department of Clinical Pharmacokinetics, Hoshi University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacokinetics, Hoshi University, Tokyo, Japan","institution_ids":["https://openalex.org/I36296616"]},{"raw_affiliation_string":"Department of Clinical Pharmacokinetics, Hoshi University","institution_ids":["https://openalex.org/I36296616"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027984186","display_name":"Yuichi Sugiyama","orcid":"https://orcid.org/0000-0002-8452-8835","observed_orcids":["https://orcid.org/0000-0002-8452-8835"]},"institutions":[{"id":"https://openalex.org/I74801974","display_name":"The University of Tokyo","ror":"https://ror.org/057zh3y96","country_code":"JP","type":"education","lineage":["https://openalex.org/I74801974"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuichi Sugiyama","raw_affiliation_strings":["Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan","Graduate School of Pharmaceutical Sciences, The University of Tokyo;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan","institution_ids":["https://openalex.org/I74801974"]},{"raw_affiliation_string":"Graduate School of Pharmaceutical Sciences, The University of Tokyo;","institution_ids":["https://openalex.org/I74801974"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5078387402"],"corresponding_institution_ids":["https://openalex.org/I4405254473"],"apc_list":{"value":3580,"currency":"USD","value_usd":3580},"apc_paid":null,"fwci":0.7219,"has_fulltext":false,"cited_by_count":91,"citation_normalized_percentile":{"value":0.64318048,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"18","issue":"6","first_page":"365","last_page":"372"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.8730000257492065,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.8730000257492065,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.11559999734163284,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10256","display_name":"Drug Solubulity and Delivery Systems","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/intestinal-first-pass-metabolism","display_name":"intestinal first-pass metabolism","score":0.8980000019073486},{"id":"https://openalex.org/keywords/cyp3a4-substrates","display_name":"CYP3A4 substrates","score":0.9940000176429749},{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.9950000047683716},{"id":"https://openalex.org/keywords/bioavailability","display_name":"bioavailability","score":0.8270000219345093},{"id":"https://openalex.org/keywords/absorbed-fraction","display_name":"fraction absorbed","score":0.7269999980926514},{"id":"https://openalex.org/keywords/hepatic-intrinsic-clearance","display_name":"hepatic intrinsic clearance","score":0.8109999895095825},{"id":"https://openalex.org/keywords/cyp3a4-inhibitors","display_name":"CYP3A4 inhibitors","score":0.902999997138977},{"id":"https://openalex.org/keywords/cyp3a4-inducers","display_name":"CYP3A4 inducers","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hepatic-blood-flow","display_name":"hepatic blood flow","score":0.8259999752044678},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.4490000009536743}],"concepts":[{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.8337323665618896},{"id":"https://openalex.org/C201253974","wikidata":"https://www.wikidata.org/wiki/Q1330121","display_name":"First pass effect","level":3,"score":0.7412294149398804},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.7405389547348022},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7020020484924316},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.679287314414978},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6125013828277588},{"id":"https://openalex.org/C2778707650","wikidata":"https://www.wikidata.org/wiki/Q412902","display_name":"P-glycoprotein","level":4,"score":0.5686401724815369},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.563554584980011},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.522388756275177},{"id":"https://openalex.org/C89311334","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Drug metabolism","level":3,"score":0.49368104338645935},{"id":"https://openalex.org/C158846371","wikidata":"https://www.wikidata.org/wiki/Q1642137","display_name":"Blood flow","level":2,"score":0.4387020766735077},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3498725891113281},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2792922258377075},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.22193607687950134},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.15666049718856812},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.1458824872970581},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.0},{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.2133/dmpk.18.365","doi":"https://doi.org/10.2133/dmpk.18.365","is_oa":false,"landing_page_url":"https://doi.org/10.2133/dmpk.18.365","pdf_url":null,"source":{"id":"https://openalex.org/S185835163","display_name":"Drug Metabolism and Pharmacokinetics","issn_l":"1347-4367","issn":["1347-4367","1880-0920"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Metabolism and Pharmacokinetics","raw_type":"journal-article"},{"id":"pmid:15618757","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15618757","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug metabolism and pharmacokinetics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8560000061988831,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W94919724","https://openalex.org/W113583849","https://openalex.org/W308582299","https://openalex.org/W1533487449","https://openalex.org/W1578896110","https://openalex.org/W1787076927","https://openalex.org/W1838282487","https://openalex.org/W1964026490","https://openalex.org/W1964470226","https://openalex.org/W1969433252","https://openalex.org/W1988986638","https://openalex.org/W1991910989","https://openalex.org/W1991992414","https://openalex.org/W1992268549","https://openalex.org/W1998131880","https://openalex.org/W2008543708","https://openalex.org/W2012627536","https://openalex.org/W2015500397","https://openalex.org/W2022435477","https://openalex.org/W2022545732","https://openalex.org/W2034295073","https://openalex.org/W2034853089","https://openalex.org/W2040944040","https://openalex.org/W2044148793","https://openalex.org/W2061407065","https://openalex.org/W2065324366","https://openalex.org/W2073965718","https://openalex.org/W2077510533","https://openalex.org/W2081082515","https://openalex.org/W2082979826","https://openalex.org/W2087795740","https://openalex.org/W2092642790","https://openalex.org/W2103126842","https://openalex.org/W2107567029","https://openalex.org/W2110187800","https://openalex.org/W2112728948","https://openalex.org/W2114089215","https://openalex.org/W2127400366","https://openalex.org/W2138644435","https://openalex.org/W2159234101","https://openalex.org/W2162740038","https://openalex.org/W6638442566"],"related_works":["https://openalex.org/W2064274693","https://openalex.org/W2509637841","https://openalex.org/W2050952591","https://openalex.org/W2085815144","https://openalex.org/W2280091719","https://openalex.org/W2295710313","https://openalex.org/W2142573506","https://openalex.org/W2079436617","https://openalex.org/W4389639495","https://openalex.org/W1985116563"],"abstract_inverted_index":{"It":[0],"is":[1,22,92,283],"suggested":[2,284],"that":[3,24,153,285],"the":[4,17,40,47,61,66,93,118,141,148,169,186,192,206,216,252],"bioavailability":[5,300],"of":[6,39,42,68,95,115,126,130,133,143,147,167,185,197,237,248,274,294,307,312],"CYP3A4":[7,43,80,127,134,144,154,286],"substrates":[8,44,155,173,203,273,287,311],"might":[9],"be":[10],"low":[11,299],"due":[12,301],"to":[13,45,231,245,302],"first-pass":[14,29,63,158,304],"metabolism":[15,30,64],"in":[16,31,81,113,117,140,160,226,233,254,272],"small":[18],"intestine,":[19],"and":[20,54,58,65,84,97,99,128,138,182,191,200],"it":[21,282],"possible":[23],"P-glycoprotein":[25],"(P-gp)":[26],"may":[27],"influence":[28],"a":[32,157,246,255,290,298],"co-operative":[33],"manner.":[34],"We":[35],"have":[36,59,289],"collected":[37],"information":[38],"pharmacokinetics":[41],"evaluate":[46],"fraction":[48],"absorbed":[49],"(Fa),":[50],"intestinal":[51,62,303],"availability":[52,56],"(Fg)":[53],"hepatic":[55,187,207,217,241,291],"(Fh)":[57],"investigated":[60],"effect":[67,159],"P-gp":[69,172,193,199,202,313],"on":[70],"this.":[71],"The":[72,195],"pharmacokinetic":[73],"data":[74],"involved":[75],"ten":[76],"compounds":[77,170],"metabolized":[78],"by":[79],"humans,":[82],"with":[83,123,261],"without":[85],"an":[86,124,131,136,232],"inhibitor":[87,125],"or":[88,174,314],"inducer.":[89],"FaFg,":[90],"which":[91,288],"product":[94],"Fa":[96],"Fg,":[98],"Fh":[100],"were":[101],"calculated":[102],"using":[103],"three":[104],"liver":[105,119,149],"blood":[106,150,188],"flow":[107,120,189],"rates":[108],"(17.1,":[109],"21.4,":[110],"25.5":[111],"mL/min/kg)":[112],"consideration":[114],"variations":[116],"rate.":[121],"Co-administration":[122],"treatment":[129],"inducer":[132],"caused":[135],"increase":[137],"decrease":[139],"FaFg":[142,181,196,211],"substrates,":[145],"regardless":[146,166,184,306],"flow,":[151],"indicating":[152],"exhibit":[156,297],"their":[161],"metabolism.":[162],"This":[163,225,267],"holds":[164],"true":[165],"whether":[168,308],"are":[171,310],"not.":[175,315],"No":[176],"relationship":[177],"was":[178,212,220,269],"observed":[179,271],"between":[180],"Fh,":[183],"rate":[190],"substrates.":[194],"both":[198],"non":[201],"decreased":[204],"as":[205],"intrinsic":[208,218,228,235,292],"clearance":[209,219,229,236,293],"increased.":[210],"markedly":[213],"reduced":[214],"when":[215],"more":[221],"than":[222,278],"100":[223,295],"mL/min/kg.":[224],"vivo":[227],"corresponds":[230],"vitro":[234],"78":[238],"muL/min/mg":[239],"human":[240,262],"microsomal":[242],"protein,":[243],"equivalent":[244],"half-life":[247],"8.9":[249],"min":[250],"for":[251],"substrate":[253],"commonly":[256],"used":[257],"metabolic":[258],"stability":[259],"test":[260],"microsomes":[263],"(1":[264],"mgMs":[265],"protein/mL).":[266],"phenomenon":[268],"not":[270],"CYP":[275],"isoforms":[276],"other":[277],"CYP3A4.":[279],"In":[280],"conclusion,":[281],"mL/min/kg":[296],"metabolism,":[305],"they":[309]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}